MedPath

Modified Enhanced Recovery After Oblique Lateral Interbody Fusion Surgery

Not Applicable
Recruiting
Conditions
Lumbar Spondylosis
Lumbar Spinal Stenosis
Lumbar Disc Herniation
Interventions
Other: routine protocol
Other: Modified ERAS protocol
Registration Number
NCT05854043
Lead Sponsor
Xuanwu Hospital, Beijing
Brief Summary

The goal of this randomized clinical trial is to investigate whether modified enhanced recovery after surgery (ERAS) in oblique lumbar interbody fusion (OLIF) can shorten the postoperative hospital stay among patients with lumbar degenerative disease.

The main questions it aims to answer are:

Whether ERAS can shorten the postoperative hospital stay. Whether modified ERAS can improve postoperative functional recovery, improve functional score and pain score, reduce hospitalization costs, improve mental state, and improve abdominal indicators, etc.

Participants will be randomized into modified ERAS group, or control group.

Detailed Description

The main questions it aims to answer are:

Whether ERAS can shorten the postoperative hospital stay. Whether modified ERAS can improve postoperative functional recovery, improve functional score and pain score, reduce hospitalization costs, improve mental state, and improve abdominal indicators, etc.

Participants will be randomized into modified ERAS group, or control group.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
96
Inclusion Criteria
  • Age 18-80 years old;
  • Lumbar degenerative diseases that meet the indications of fusion surgery;
  • Patients who are suitable for OLIF surgery;
  • Patients who have actually completed OLIF surgery;
  • The number of fusion segments is less than or equal to two;
  • There was no basis for serious diseases of brain, lung, kidney and other important organs, and preoperative American Society of Anesthesiologists (ASA) score was I-III;
  • Agree to participate in the study and sign the informed consent form.
Exclusion Criteria
  • Patients undergoing lumbar fusion surgery due to spinal trauma;
  • Patients undergoing lumbar fusion surgery due to spinal tumor resection;
  • Revision surgery;
  • The number of fused segments is more than 2;
  • Simultaneous lumbar fusion via other approaches, such as transforaminal lumbar interbody fusion (TLIF), posterior lumbar interbody fusion (PLIF), anterior lumbar interbody fusion (ALIF), etc.;
  • Pregnancy or perinatal period;
  • Blood system diseases lead to coagulation dysfunction;
  • Combined with other diseases, life expectancy less than 2 years;
  • Patients is participating in other clinical trials.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
control grouproutine protocolIn this group, patients will be treated with routine protocol.
ERAS groupModified ERAS protocolIn this group, patients will be treated with modified ERAS protocol.
Primary Outcome Measures
NameTimeMethod
Postoperative hospital stayFrom the date of surgery to discharge, assessed up to 1 month

The length of hospital stay post-operation.

Secondary Outcome Measures
NameTimeMethod
Postoperative functional recoveryFrom the date of surgery to discharge, assessed up to 1 month

Evaluate the functional recovery through 6 Minutes Walk Distance. A longer walk distance indicates better functional recovery.

Postoperative pain scoreFrom the date of surgery to 1 year post-operation

Postoperative VAS at different time points for pain assessment. From 0-10, 0 indicates no pain, 10 indicates the most severe pain.

Postoperative life quality assessmentFrom the date of surgery to 1 year post-operation

Postoperative EuroQol-5 Dimensions (EQ-5D) at different time points for life quality assessment.

Postoperative lumbar neurological function assessmentFrom the date of surgery to 1 year post-operation

Postoperative Japanese Orthopedics Association (JOA) at different time points for life quality assessment. From 0-29, A lower score indicates more dysfunction.

Trial Locations

Locations (1)

Xuanwu hospital capital medical university

🇨🇳

Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath